<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article124</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/MOMENTUM_3" style="display:block; margin-bottom:10px;">MOMENTUM 3 Original</a></li>
<h2><strong>MOMENTUM 3</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Clinical Outcomes in Advanced Heart Failure Patients with Centrifugal-Flow vs. Axial-Flow Pump". <br/>
The New England Journal of Medicine. <br/>
ClinicalTrials.gov number, NCT02224755.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does a fully magnetically levitated centrifugal-flow pump improve clinical outcomes compared to a mechanical-bearing axial continuous-flow pump for patients with advanced heart failure?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with advanced heart failure, a fully magnetically levitated centrifugal-flow pump is superior to a mechanical-bearing axial-flow pump, with higher survival rates free of disabling stroke or reoperation due to malfunctioning device. <br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Left ventricular assist systems are indicated for advanced heart failure patients as a bridge to transplantation or as destination therapy.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, randomized noninferiority and superiority trial<br/>
- 366 patients with advanced heart failure allocated to centrifugal-flow pump (n=190) or axial-flow pump (n=176)<br/>
- Primary endpoint: Survival at 2 years free of disabling stroke or reoperation due to device malfunction<br/>
- Noninferiority margin: -10 percentage points for the risk difference<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Adults with advanced heart failure refractory to medical management<br/>
- Excluded if active infection, irreversible organ dysfunction, or needing biventricular support<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients were randomized to the centrifugal-flow pump (HeartMate 3) or axial-flow pump (HeartMate II), with antithrombotic treatment including aspirin and warfarin.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary outcome (intention-to-treat): The centrifugal-flow pump group demonstrated a higher rate of the primary endpoint (79.5%) compared to the axial-flow pump group (60.2%) (P&lt;0.001 for noninferiority and superiority).<br/>
- Secondary outcomes: Lower rates of reoperation in the centrifugal-flow pump group (1.6% vs. 17.0%, P&lt;0.001) and overall rate of stroke (10.1% vs. 19.2%, P=0.02).<br/>
- There was no significant difference in the incidence of disabling stroke or death between the two groups.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Lack of blinding, which may have introduced bias in the study.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The study was funded by Abbott, the manufacturer of the HeartMate systems.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
